Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

doi: 10.1186/s13046-018-0999-5

Figure Lengend Snippet: Paclitaxel and its combination with nintedanib increased median survival in the advanced metastatic breast cancer LM2–4 model. a ) Kaplan-Meier survival curves and median survival values. Paclitaxel (PTX) significantly increased median survival compared to the control group ( p = 0.033; Log-rank (Mantel Cox) Test, n = 8–10). Combination therapy increased median survival (81 days vs 60.5 days, control group) but it did not reach significance. Treatment started around 40 days after cell implantation. b) Effect of sunitinib alone and when combined with PTX in the advanced metastatic LM2–4 breast cancer model. Kaplan-Meier survival curves and median survival values. Modified from Guerin et al., 2013 . PTX alone increased survival whereas sunitinib alone did not, and adding sunitinib to PTX did not result in increased efficacy

Article Snippet: The EMT-6 (ATCC® CRL-2755TM) mouse breast cancer cell line and the derived variant EMT-6/CDDP -selected in vivo for acquired resistance to cisplatin [ ]-, were cultured in DMEM medium with 5% FBS at 37 °C in 5% CO 2.

Techniques: Control, Modification

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

doi: 10.1186/s13046-018-0999-5

Figure Lengend Snippet: Improvement of immunotherapy efficacy when treating primary tumors with nintedanib combination therapy . a ) Tumor growth in the primary EMT-6 breast cancer model. Treatment was started when average tumor volume was 120mm 3 , around 7 days after cell implantation. Statistical analysis on day 27. ANOVA followed by Tukey’s Multiple Comparison Test * p < 0.05, ** p < 0.01. Data are presented as means ± SD, n = 6. Region of flat line in the curves means that tumor in remaining mice had regressed, and in the case of mice treated with PD-L1 antibody, tumors grew back. Mice were treated with nintedanib and/or paclitaxel (PTX) for 70 days, and then treatment stopped. b) Tumor growth in the primary EMT-6/CDDP model. Treatment was started when average tumor volume was 120mm 3 , 7 days after cell implantation. Statistical analysis on day 27. Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test, ** p < 0.01. Data are presented as means ± SD, n = 9–12. c-f) Effect of nintedanib, paclitaxel, anti-PD-L1 and the drug combinations on c) Vascularity; d) Proliferation; e) CD8+ tumor infiltrating cells; and f) Level of Necrosis. Histology and immunohistochemistry analyses were performed on tumor samples obtained from mice implanted with EMT-6/CDDP cells. Treatment was started when average tumor volume was 120mm 3 and all mice were sacrificed after 10 days of treatment. The Mann-Whitney test was used for statistical analyses. Data are presented as means ± SD, n = 6–7

Article Snippet: The EMT-6 (ATCC® CRL-2755TM) mouse breast cancer cell line and the derived variant EMT-6/CDDP -selected in vivo for acquired resistance to cisplatin [ ]-, were cultured in DMEM medium with 5% FBS at 37 °C in 5% CO 2.

Techniques: Comparison, Immunohistochemistry, MANN-WHITNEY